A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors (Journal article)

Kalbakis, K./ Pappas, P./ Kouroussis, C./ Vamvakas, L./ Kalykaki, A./ Vardakis, N./ Nikolaidou, M./ Marselos, M./ Georgoulias, V./ Mavroudis, D.

PURPOSE: To evaluate the maximum tolerated doses (MTD) and the dose-limiting toxicities (DLT) of the combination of pegylated liposomal doxorubicin (PEG-LD), paclitaxel and oxaliplatin (L-OHP) administered every 2 weeks in patients with advanced solid tumors. METHODS: Thirty-nine pretreated patients with advanced solid tumors received escalated doses of PEG-LD (10-16 mg/m(2)), paclitaxel (100-120 mg/m(2)) and L-OHP (50-70 mg/m(2)) every 2 weeks. As one cycle of treatment was considered the administration of both drugs on days 1 and 15 of a 4-week cycle. RESULTS: The MTDs were PEG-LD 14 mg/m(2), paclitaxel 120 mg/m(2) and L-OHP 70 mg/m(2). Neutropenia was the DLT in all but one case with only one episode of febrile neutropenia and no toxic deaths. Four (4%) and 13 (12%) cycles were complicated by grades 4 and 3 neutropenia, respectively. Grades 2-3 fatigue and neurotoxicity occurred in 13 and 12% of cycles, respectively. Responses were observed in patients with breast, endometrial and ovarian carcinomas. CONCLUSIONS: This is a quite well-tolerated regimen which merits further evaluation in phase II studies.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Adult,Aged,*Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse,effects/pharmacokinetics/therapeutic use,Disease-Free Survival,Dose-Response Relationship, Drug,Doxorubicin/administration & dosage/adverse effects/pharmacokinetics/therapeutic,use,Drug Administration Schedule,Female,Humans,Male,Middle Aged,Neoplasm Invasiveness,Neoplasms/*drug therapy/pathology,Organoplatinum Compounds/administration & dosage/adverse,effects/pharmacokinetics/therapeutic use,Paclitaxel/administration & dosage/adverse effects/pharmacokinetics/therapeutic,use
URI: https://olympias.lib.uoi.gr/jspui/handle/123456789/24356
ISSN: 0344-5704
Link: http://www.ncbi.nlm.nih.gov/pubmed/17960381
http://www.springerlink.com/content/7447319178378k8w/fulltext.pdf
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Kalbakis-2008-A dose escalation an.pdf390.85 kBAdobe PDFView/Open    Request a copy


 Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/24356
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.